Clinical aspects of the use of insulin glargine (300 ED/ml) in patients with type 2 diabetes: from research to outpatient practice
AbstractInsulin therapy for type 2 diabetes has a special impotance. Achievement of glycemic targets with the timely appointment of insulin not only reduces the risk of micro- and macrovascular complications of this pathology, but also contributes to the preservation of the secretory reserve of pancreatic β-cells by eliminating glucose toxicity. The leading role in the formation of a stable glycemic background belongs to basal insulin as a prototype of basal secretion of insulin. Despite the obvious advantages of the already existing basal insulin analogues, when they are used, many patients with type 2 diabetes continue to experience hypoglycemia, increased appetite, and, as a consequence, weight gain. The article presents a clinical analysis of the use of insulin glargine at a concentration of 300 U/ml (glargine U-300) in 144 patients with type 2 diabetes in a routine outpatient setting. The features and points of control are described in detail in various clinical situations: when initiating insulin therapy, transferring to glargine U-300, which will allow using the new basal insulin preparation with maximum efficiency.
Keywords:diabetes mellitus type 2, basal insulin preparations, practical application, clinical features, glucose toxicity, initiation of insulin therapy, NPH-insulin, Lantus, Toujeo, glargine U-300, glargine U-100
Endocrinology: News, Opinions, Training. 2018; 7 (3): 39-54.
doi: 10.24411/2304-9529-2018-13004.